European defence company shares fall amid Ukraine peace talk hopes; Novo Nordisk reports Ozempic fails to help with Alzheimer’s – as it happened

Talks in Geneva producing an “updated and refined peace framework” between the US and Ukraine weighed on European defence names (Rheinmetall down ~3.5% at open and later >5%, Renk down ~3.85–4%, BAE and Babcock down 1–3%) while European gas futures fell below €30/MWh to an 18‑month low and Brent eased 0.7% to $62.08. Novo Nordisk reported two phase‑3 semaglutide Alzheimer trials failed to show statistically significant slowing of decline, prompting a material share decline (reported falls ~6–10% in different updates), Unimetals filed for compulsory liquidation endangering ~650 jobs, and Fitch downgraded ASDA’s parent to B (negative outlook). Monetary and policy moves include a Bank of Israel rate cut to 4.25% and ongoing UK budget scrutiny ahead of Wednesday’s fiscal statement; Ferrexpo jumped ~21% on hopes of a Ukraine breakthrough. Investors should expect sector rotation (defence weakness, energy/commodities repricing, idiosyncratic corporate risk in healthcare and retail credit) rather than a broad market impulse.

Analysis

Market structure: Security of supply narratives shifting from tail‑risk premia to near‑term demand repricing. Lower gas and oil levels reduce input-cost risk for European industrials and utilities while compressing energy producers’ near‑term margins; concurrently defence OEMs face order‑timing risk as political risk premia fall, pressuring short‑cycle revenue recognition and aftermarket pricing power.

Risk assessment: Key tail events include a breakdown of talks (rapid re‑risking of defence and commodity volatility), an OPEC+ surprise cut (re‑inflates energy), or a cascaded retail credit default following ASDA parent distress. Immediate (days) volatility will centre on defence and commodities, medium (weeks–months) on credit spreads and earnings revisions, long (quarters) on capex cycles and pharma R&D pipeline re‑valuation.

Trade implications: Implement relative trades that monetize repricing rather than directional macro: short short‑dated defence exposure vs long Ukraine/commodity beneficiaries; express idiosyncratic pharma view via time‑limited option structures to avoid binary trial risk; underweight UK retail credit and prefer government bills into the budget event. Use defined‑risk option spreads and tight stop rules to manage gamma in this risk‑off regime.

Contrarian angles: The market likely overprices immediate procurement cuts — defence budgets are sticky and multi‑year; energy price dips may trigger capex pullbacks that support prices in 3–12 months. Novo Nordisk’s core GLP‑1 cash flows remain intact, so a measured long dated call spread is a plausible asymmetric play while avoiding headline binary risk.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio short position in Rheinmetall (RHM.DE) via a 3‑month put spread (buy 1 ATM put, sell 1 15% OTM put) to cap cost; target 15–20% downside within 4–8 weeks, stop‑loss at 8% adverse move.
• Establish a 2–3% long position in Ferrexpo (FXPO.L) or equivalent iron‑ore exposure, target +30% in 3 months on de‑risking headlines, set stop‑loss at 12% and scale out at +25%.
• Deploy a conservative asymmetric long on NVO: buy a 12‑month call 10% OTM and sell a 12‑month call 25% OTM (1–1 ratio), size 1% portfolio; exit on 30–50% premium gain or at maturity to capture GLP‑1 franchise resilience while limiting binary downside.
• Trim 1–2% gross exposure to UK retail/consumer discretionary equities and increase short‑duration cash/UK T‑bills ahead of the UK budget; if ASDA‑parent 5y CDS widens >200bp, add an additional 0.5–1% hedge to credit exposure.